A Phase 4 interventional study of Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg) and ASA 100 mg qd in Cerebrovascular Accident, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-19.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing aspirin in Stroke — 8 open to participants now, 10 under way, 3 of them phase 3. Aspirin · Stroke.
Among the 42 studies testing aspirin in Stroke, this one is the 22nd largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2007, is one of 17 in phase 4, and was the 6th registered.
8,279 studies on the registry are indexed under Stroke; 2,066 are open to participants now.
Browse Stroke studies →8 of the 42 studies testing aspirin in Stroke are open now, in 5 countries. Recruiting first, the newest first:
Christian Medical College and Hospital, Ludhiana, India · Sites in India
Ages 18–99
Chinese Academy of Medical Sciences, Fuwai Hospital · Sites in China
Xueli Cai · Sites in China
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 1,421 Stroke studies recruiting now, 698 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 13 · Phase 4 17
First in 2002; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 551 is above the median of 49 across 6,045 interventional studies indexed under Stroke.
Median enrollment 675 across the 41 interventional studies. Of the 24 that completed or were terminated, 6 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 42 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
23 studies in Stroke by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 23 studies in Stroke by Boehringer Ingelheim, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 4, and was the 7th registered.
Boehringer Ingelheim’s Stroke studies by the year they started, since 1998.
3 of the studies testing aspirin in Stroke that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT04796714University Hospital, BordeauxAntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE | 2027-05-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies testing aspirin in Stroke, from their registry updates:
Among Boehringer Ingelheim’s 23 in Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting. They argue that clinical experience with sub-acute Aggrenox treatment is limited and poorly documented when compared with sub-acute acetylsalicylic acid (ASA) treatment. However, long term treatment (started after 3-6 months after stroke/TIA) with Aggrenox was safe and superior to ASA treatment in preventing recurrent strokes. There is no evidence for ASA to prevent from neurological progression after stroke during the first 3 months. Results from a cohort study suggest that starting Aggrenox within 72 hours after stroke predicts clinical improvement in the National Institute of Health Stroke Scale (NIHSS) at discharge from the hospital. Dipyridamole suppresses acute inflammatory responses to stroke.
This study is designed to investigate the tolerability and efficacy of a secondary stroke prevention treatment with Aggrenox when initiated within 24 hours of stroke onset on a stroke unit compared to later initiation after a 7 day ASA treatment and outside off a stroke unit setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Clinical diagnosis of ischaemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Symptoms must be distinguishable from an episode of generalised ischaemia (i.e. syncope), seizure, or migraine disorder.
Main inclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug page: Aspirin
Telephone Modified Rankin Scale (Centralised, Blinded Assessment)
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)
Time frame: 90 days
Change From Baseline in NIHSS (National Institutes of Health Stroke Scale)
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)
Time frame: Baseline and 90 days
Patients With Relevant Event (Death, Non-fatal Stroke, Transient Ischaemic Attack (TIA), Myocardial Infarction (MI), Bleeding)
Time frame: 90 days
Telephone Modified Rankin Scale (Centralised, Blinded Assessment) at Day 8
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)
Time frame: 8 days
Change From Baseline in NIHSS (National Institutes of Health Stroke Scale) at Day 8
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)
Time frame: Baseline and 8 days
Change of Special Biochemical Laboratory Value- CRP
Changes of special biochemical laboratory values (CRP) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory
Time frame: 8 days
Change of Special Biochemical Laboratory Value- MMP-9
Changes of special biochemical laboratory value (MMP-9) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory
Time frame: 8 days
Change of Special Biochemical Laboratory Value - MCP-1
Changes of special biochemical laboratory value (MCP-1) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory
Time frame: 8 days
Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 8
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).
Time frame: Baseline and day 8
Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 90.
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).
Time frame: Baseline and day 90
Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 8
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.
Time frame: Baseline and day 8
Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 90
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.
Time frame: Baseline and day 90
551 patients enrolled, 548 randomized, 543 treated; analysis is based on treated patients
| Milestone | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Started | 260 | 283 |
| Completed | 168 | 184 |
| Not completed | 92 | 99 |
| Withdrew: Adverse event | 40 | 58 |
| Withdrew: Protocol violation | 30 | 26 |
| Withdrew: Lost to follow-up | 12 | 4 |
| Withdrew: Withdrawal by subject | 10 | 9 |
| Withdrew: Other | 0 | 2 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)
| participants | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| 0 | 58 | 70 |
| 1 | 75 | 84 |
| 2 | 50 | 62 |
| 3 | 30 | 16 |
| 4 | 31 | 32 |
| 5 | 6 | 4 |
| 6 | 4 | 5 |
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)
| Units on a scale | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change From Baseline in NIHSS (National Institutes of Health Stroke Scale) | -2 (-4 to 0) | -2 (-3 to 0) |
| participants | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Patients With Relevant Event (Death, Non-fatal Stroke, Transient Ischaemic Attack (TIA), Myocardial Infarction (MI), Bleeding) | 38 | 28 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. Best value - 0 (No symptoms), worst value - 6 (Dead)
| participants | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| 0 | 46 | 47 |
| 1 | 59 | 74 |
| 2 | 42 | 52 |
| 3 | 39 | 38 |
| 4 | 51 | 44 |
| 5 | 12 | 8 |
| 6 | 0 | 2 |
| Missing | 5 | 8 |
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead)
| units on a scale | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change From Baseline in NIHSS (National Institutes of Health Stroke Scale) at Day 8 | -1.0 (-3.0 to 0.0) | -1.0 (-3.0 to 0.0) |
Changes of special biochemical laboratory values (CRP) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory
| mg/L | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change of Special Biochemical Laboratory Value- CRP | 1.27 (1.06 to 1.52) | 1.17 (1.00 to 1.38) |
Changes of special biochemical laboratory value (MMP-9) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory
| ng/mL | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change of Special Biochemical Laboratory Value- MMP-9 | 0.974 (0.884 to 1.07) | 0.983 (0.89 to 1.08) |
Changes of special biochemical laboratory value (MCP-1) from baseline to day 8 - centralised, blinded assessment by a specialised central clinical laboratory
| µg/mL | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change of Special Biochemical Laboratory Value - MCP-1 | 1.06 (1.01 to 1.10) | 1.08 (1.03 to 1.13) |
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).
| mL | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 8 | 0.4100 (0.1050 to 2.0450) | 0.3300 (0.0200 to 1.3500) |
MRI was performed to assess growth in stroke lesion volume by fluid-attenuated inversion recovery (FLAIR).
| mL | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change From Baseline in FLAIR (Fluid-Attenuated Inversion Recovery) at Day 90. | 0.1900 (0.0000 to 1.1400) | 0.1150 (0.0000 to 0.9000) |
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.
| mL | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 8 | -0.0600 (-0.7050 to 0.5650) | 0.0000 (-0.5000 to 0.3000) |
MRI was performed to assess growth in stroke lesion volume by diffusion-weighted imaging (DWI). DWI was to give evidence of the development of the ischaemic lesion corresponding to the evolved stroke.
| mL | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Change From Baseline in DWI (Diffuse-Weighted Imaging) at Day 90 | -0.8400 (-2.0850 to -0.3550) | -0.7100 (-1.9300 to -0.2600) |
Collected over Up to 90 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aspirin for 7 Days, Followed by Aggrenox | — | 48/260 (18.5%) | 60/260 (23.1%) |
| Aggrenox | — | 45/283 (15.9%) | 119/283 (42%) |
| Event | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 15/260 | 5/283 |
| Carotid artery stenosisNervous system disorders | 5/260 | 2/283 |
| Transient ischaemic attackNervous system disorders | 4/260 | 2/283 |
| Myocardial infarctionCardiac disorders | 1/260 | 4/283 |
| Ischaemic strokeNervous system disorders | 3/260 | 1/283 |
| PneumoniaInfections and infestations | 3/260 | 0/283 |
| Atrial septal defectCongenital, familial and genetic disorders | 3/260 | 3/283 |
| Atrial fibrillationCardiac disorders | 2/260 | 3/283 |
| Cardiac failureCardiac disorders | 1/260 | 3/283 |
| DepressionPsychiatric disorders | 2/260 | 1/283 |
| Event | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox |
|---|---|---|
| HeadacheNervous system disorders | 53/260 | 105/283 |
| NauseaGastrointestinal disorders | 14/260 | 29/283 |
| VomitingGastrointestinal disorders | 10/260 | 26/283 |
| Age, Continuous(Years) | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox | Total |
|---|---|---|---|
| Mean | 68.3 ± 11.5 | 66.5 ± 11.4 | 67.3 ± 11.5 |
| Sex: Female, Male(Participants) | Aspirin for 7 Days, Followed by Aggrenox | Aggrenox | Total |
|---|---|---|---|
| Female | 95 | 109 | 204 |
| Male | 165 | 174 | 339 |
The record gives a start of Jul 2007 and a primary completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin